EP0406275A4 - Teat dip - Google Patents

Teat dip

Info

Publication number
EP0406275A4
EP0406275A4 EP19890903663 EP89903663A EP0406275A4 EP 0406275 A4 EP0406275 A4 EP 0406275A4 EP 19890903663 EP19890903663 EP 19890903663 EP 89903663 A EP89903663 A EP 89903663A EP 0406275 A4 EP0406275 A4 EP 0406275A4
Authority
EP
European Patent Office
Prior art keywords
composition
teat
teat dip
fatty acid
bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19890903663
Other languages
English (en)
Other versions
EP0406275A1 (fr
Inventor
Bruce Kefford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agriculture Victoria Services Pty Ltd
Original Assignee
Daratech Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daratech Pty Ltd filed Critical Daratech Pty Ltd
Publication of EP0406275A1 publication Critical patent/EP0406275A1/fr
Publication of EP0406275A4 publication Critical patent/EP0406275A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/06—Unsaturated carboxylic acids or thio analogues thereof; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration

Definitions

  • This invention relates to animal health care products and in ⁇ particular to a teat dip for dairy cows.
  • mastitis The spread of bacterial infection from cow teats during the milking operation results in the spread of the infectious mammary disease known as mastitis.
  • the spread of this disease is usually reduced -by the use of known bacteriocides such as chlorine and iodine based compositions. These compositions are usually administered to the teat after removal of the milking cup by dipping or spraying the teat. It is believed these bacteriocides kill a substantial number of bacteria including mastitis pathogens, and thus reduce the spread of bacteria into the mammary gland where mastitis may become evident. There are usually insignificant residual effects of these bacteriocides between milkings. There are problems with the use of these agents including irritation to the teat and teat cracking. To alleviate these problems, emollient additives such as glycerine may be included in these compositions. However, even with the use of these emollients skin irritation can still occur.
  • this invention provides in one form a teat dip composition comprising an oil-in-water emulsion wherein the oil phase comprises an unsaturated fatty acid having a carbon chain length in the range C16 to C20.
  • the fatty acid has a chain length C18 and more preferably the fatty acid is linolenic acid.
  • the composition includes stabilising amounts of surfactants to enable a stable oil-in-water emulsion to be formed.
  • the surfactants include a non-ionic surfactant, in particular a polyethylene oxide derivative.
  • the surfactants are substantially non-ionic.
  • suitable surfactants are sorbitan onolaurate and ethoxylates thereof.
  • Surfactants are selected on the basis of their ability to form stable oil-in-water emulsions. Generally it is best if at least two surfactants are used, one with a HLB value less than 10 and one with a HLB value i .excess of 10. It is important that the surfactants when used in the teat dip composition do not result in unacceptable residues in milk.
  • the surfactants are used at art recognised levels and are typically of the order 1-20% by weight of oil phase. It is believed the surfactants also inhibit the adhesion of mastitis pathogens thereby improving the efficacy of the composition.
  • the pH of the composition is such that in use irritation to the teat is minimal and a pH in the range 6-8 is found to be particularly suitable.
  • the relative ratios of oil to water phases are not critical to the working of the composition although from a cost eff ctiveness viewpoint an oil-in-water ratio in the range of 1/5 to 1/25 is found to be useful in practice.
  • the composition could be packaged for sale at a higher oil-in-water ratio and diluted before use by the dairy farmer by the addition of water. Though this can cause some emulsion stability problems where water quality is poor.
  • deionised water is used in the compositions of the present invention. Though less preferred it is possible to sell the oil phase which is emulsified before use by the customer.
  • the fatty acids suitable for the compositions of the present invention can be selected from fatty acids derived from naturally occurring tri-glyceride oils such as vegetable oils, for example, linseed, perilla, soya and safflower. Synthetic unsaturated fatty acids may also be used. One particularly suitable active fatty acid is hydrolysed linseed oil. It will be appreciated that with both the synthetic and natural fatty acids, significant range of compositions of fatty acids can occur. Significant proportions of saturated fatty acid may be present. These are not unduly detrimental to the composition, other than diminishing the level of active unsaturated fatty acid in a given oil phase.
  • the unsaturated fatty acid may be selected, for example, from lauroleic, myristoleic, palmitoleic, oleic, ricinoleic, gadoleic, erueic.
  • the level of unsaturation is (-4H) or (-6H) such as in linoleic, linolenic, eleostearic, licanic and arachidic.
  • at least 20% by weight of the oil phase is unsaturated fatty acid and more preferably at least 30%.
  • compositions of the present invention are found to be effective in reducing the spread of mastitis within a herd of dairy cows and at the same time not increasing teat cracking. It is also noted that residues from the present compositions, in particular unsaturated fatty acids, which may ultimately be introduced into milk are believed to be non-harmful and indeed may be already present at low levels in milk. The present compositions also have a residual effect between milkings that is greater than the prior art compositions.
  • compositions such as glycerol. This may be present when hydrolysed vegetable oil is used.
  • the unsaturated fatty acid is effective in killing the Staphylococus aureus and Streptococci (gram positive bacteria) believed to contribute to mastitis disease control by post milking hygiene.
  • Other bacteria particularly gram negative bacteria are relatively unaffected.
  • some bacterial resistance remains from the unkilled bacteria.
  • harmless bacteria remain as a protective coating on the teats.
  • the compositions of the present invention provides some residual bacterial protection between milkings.
  • a teat dip composition was prepared by dissolving: . hydrolysed linseed oil fatty acid 5 . Tween 20 1
  • Span 60 is added to the hydrolysed linseed oil, heated and stirred until the Span 60 is dissolved, the Tween 20 is then added to this solution, after which this mixture is added to an equal volume of deionised water and agitated. An emulsion formed which was then diluted with more deionised water to lead to 93 parts of water in the overall composition. The resulting teat dip composition was stable over a period of several weeks with no evidence of the emulsion breaking. The composition was evaluated in vitro by appropriate cell counts of S-aureus bacteria. As controls water, chlorine and an iodine based commercial treatments were used. Generally the results showed the composition to be more effective in killing the bacteria than either of the commercial control materials.
  • Tween 20 is a polyethylene oxide sorbitan monolaurate, a non-ionic surfactant of HLB 16.7 manufactured by ICI Speciality Chemical Industries N.V. Approximately 20 ethylene oxide units are condensed onto the sorbitan.
  • Span 60 is sorbitan monostearate, a non-ionic surfactant of HLB .7 manufactured by ICI Speciality Chemical Industries N.V. Cone, (ug/ml) at which no growth was seen on agar plates
  • Streptococcus aqalactiae were much more sensitive to the active ingredient and Example 1 than the strains of Staphylococcus aureus.
  • a teat dip should prove effective in reducing the recoverable number of bacteria (mastitis pathogens) which have been experimentally applied to the teat.
  • a mastitis pathogen Staphylococcus aureus
  • Example 1 The composition of Example 1 was tested at the Gilbert Chandler Institute of Dairy Technology, Werribee, for its effect on cheese starter and yoghurt making bacteria. The effect of test compounds on these bacteria is measured in terms of the change in pH during the cheese yoghurt making. If the cheese containing a test compound, at a given concentration, has a pH at the end of the incubation > 0.2 units higher than the control batch then the test compound had a significant effect at that concentration. It was found with the composition of Example 1 that at concentrations ⁇ 1 ul/ml of milk there was no significant effect on cheese or yoghurt making. This concentration (1 ul composition of
  • Example 1/ml of milk represents a dilution of 1 :1000.
  • 20 ml of composition of Example 1 would be required to significantly affect cheese and yoghurt making.
  • Example 1 When the composition of Example 1 was tested on the two herds for its effect on teat skin, swabs were also taken of the teats that had been treated twice daily with either the composition of Example 1 , iodine (5000 ppm) or untreated for 8 weeks. At the end of the experiment swabs of all teats were taken 14 hours after treatment and serial dilutions of fluid from them were plated onto staphylococcal selective medium (sheep blood agar).
  • staphylococcal selective medium staphylococcal selective medium
  • Swabs from the composition of Example 1 treated teats when compared to iodine—treated teats have:
  • Swabs from the composition of Example 1 treated teats when compared with untreated teats have:
  • Example 1 The composition of Example 1 is more effective than iodine in holding staphylococcal numbers down between milkings.
  • Example 1 The composition of Example 1 promotes the survival of bacilli (and possibly other less pathogenic bacteria on teats which may lead to reduced reinfection of the teat through competition.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La composition pour bain pour trayon décrite est destinée à être utilisée dans le traitement de la mastite chez les vaches laitières. Sous sa forme prête pour l'application, cette composition se présente comme une émulsion d'huile dans l'eau. La phase d'huile contient un acide gras non saturé, constitué par exemple par un acide gras d'huile de lin, dont la longueur de la chaîne de carbones est comprise entre 16 et 20.
EP19890903663 1988-03-21 1989-03-21 Teat dip Withdrawn EP0406275A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPI734288 1988-03-21
AU7342/88 1988-03-21

Publications (2)

Publication Number Publication Date
EP0406275A1 EP0406275A1 (fr) 1991-01-09
EP0406275A4 true EP0406275A4 (en) 1992-05-06

Family

ID=3772936

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19890903663 Withdrawn EP0406275A4 (en) 1988-03-21 1989-03-21 Teat dip

Country Status (3)

Country Link
EP (1) EP0406275A4 (fr)
NZ (1) NZ228431A (fr)
WO (1) WO1989008981A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2899061B1 (fr) * 2006-03-31 2009-07-31 Cid Lines Nv Composition d'hygiene et/ou comestique et/ou desinfectante contenant au moins un agent anti-parasitaire repulsif et/ou insectifuge.
US9913859B1 (en) 2013-03-15 2018-03-13 Webco Chemical Corporation Dairy animal teat disinfectant
CN111991385A (zh) * 2020-08-17 2020-11-27 暨南大学 棕榈油酸在抑制水产病原菌中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3769420A (en) * 1970-12-30 1973-10-30 Schuyler Dev Corp Mastitis treatment
GB1561423A (en) * 1976-08-25 1980-02-20 Mundipharma Ag Sprayable germicidal foam compositions
US4668419A (en) * 1984-12-17 1987-05-26 Moseman Roger E Liquid foot treatment composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3949071A (en) * 1972-09-18 1976-04-06 Ferraton Aktieselskab Method and composition for treating burns and scalds
ZA784489B (en) * 1977-08-18 1980-03-26 R Brown Improved styptic composition
DE3367152D1 (en) * 1982-05-25 1986-12-04 Edward Sturdy Wilson Improvements in or relating to iodophors
NZ205076A (en) * 1982-08-09 1985-04-30 Univ California Protecting and healing gastro-duodenal mucosa and the liver of mammals using a fatty acid
CH655656B (fr) * 1982-10-07 1986-05-15
DE3381777D1 (de) * 1982-12-09 1990-09-06 Advanced Drug Tech Einfach absorbierbare fettsaeureemulsionen.
US4784845A (en) * 1985-09-16 1988-11-15 American Cyanamid Company Emulsion compostions for the parenteral administration of sparingly water soluble ionizable hydrophobic drugs
CA1331559C (fr) * 1986-04-21 1994-08-23 Jon Joseph Kabara Compositions et methodes pour la conservation antimicrobienne
CA1302280C (fr) * 1986-04-21 1992-06-02 Jon Joseph Kabara Compositions et methodes pharmaceutiques antimicrobiennes topiques

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3769420A (en) * 1970-12-30 1973-10-30 Schuyler Dev Corp Mastitis treatment
GB1561423A (en) * 1976-08-25 1980-02-20 Mundipharma Ag Sprayable germicidal foam compositions
US4668419A (en) * 1984-12-17 1987-05-26 Moseman Roger E Liquid foot treatment composition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL PATENTS INDEX, BASIC ABSTRACTS JOURNAL Section Ch, Week D50, 10 February 1982 Derwent Publications Ltd., London, GB; Class C, AN 92089 D/50 & JP-A-56 140 911 (NISSHIN OIL MILLS KK) 4 November 1981 *
See also references of WO8908981A1 *

Also Published As

Publication number Publication date
NZ228431A (en) 1991-08-27
EP0406275A1 (fr) 1991-01-09
WO1989008981A1 (fr) 1989-10-05

Similar Documents

Publication Publication Date Title
US4945110A (en) Membrame-forming veterinary antibacterial teat dip
US4446153A (en) Skin sanitizing composition and method of using
US4012504A (en) Iodine mineral oil solution for preventing bovine mastitis
US3993777A (en) Aqueous compositions to aid in the prevention of bovine mastitis
US3950554A (en) Treatment of mastitis in bovine udders
US5534266A (en) Bovine teat dip
US10744085B2 (en) Intra-mammary teat sealant formulation and method of using same to reduce or eliminate visual defects in aged cheeses
EP0693878A1 (fr) Solution pour immerger les pis afin de constituer une barriere d'iode
WO1998009520A1 (fr) Compositions antimicrobiennes
US5308868A (en) Teat dip
JPH08175989A (ja) 乳房炎の予防のための組成物
WO1989008981A1 (fr) Bain pour trayon
US4067967A (en) Composition for topical application to humans and animals
AU646880B2 (en) Teat treating compositions, production and use
AU622664B2 (en) Teat dip
US9138004B2 (en) Chloramine T based teat cleaner and related process
EP0095377B1 (fr) Iodophores
DK157113B (da) Praeparat til yverpleje og pattedesinfektion af malkekvaeg paa basis af jodholdige desinfektionsmidler og hudplejemidler
Pankey Teat dips and the practitioner
AU2014202666B2 (en) Intra-mammary teat sealant formulation and method of using same to reduce or eliminate visual defects in aged cheeses
US4942177A (en) Composition and method for cleaning and sanitizing the teats of milk producing animals
JPH08231392A (ja) 乳頭保護剤組成物
CA1053580A (fr) Solution aqueuse pour la prevention de la mastite chez les bovins
EP1833298B1 (fr) Emulsions anti-bacteriennes concentrees stables de monocaprine dans de l'eau
Boddie et al. Efficacy of a fatty acid-lactic acid postmilking teat germicide in reducing incidence of bovine mastitis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19900921

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19920318

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19930323

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19930803